Curaleaf Posts $260.3 Million In Q1 Revenue, Beating Analyst Expectations

Curaleaf Holdings (CSE: CURA) this evening reported its first quarter financial results, with the company reporting total revenue of $260.3 million, beating consensus estimates. Adjusted EBITDA meanwhile came in at $62.6 million, beating consensus estimates of $60.2 million.

Revenues reported for the quarter represents a beat on the prior guidance of $250 to $255 million, while also marking a 13% gain from the fourth quarter revenue figure of $230.3 million. Year over year meanwhile revenue at Curaleaf grew from $96.5 million, a 170% increase.

Gross margins on cannabis sales meanwhile hit 49%, with cost of goods sold coming in at $131.9 million, representing a gross profit of $128.0 million before the impact of biological assets. After operating expenditures of $107.1 million, Curaleaf reported an income from operations of $33.7 million.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

However, after factoring in interest expense of $12.2 million, interest expenses related to lease liabilities of $8.6 million, and income tax expenses of $30.7 million, the company recorded a net loss of $17.2 million.

Looking to the balance sheet, Curaleaf currently has $314.6 million in cash on the books, as well as receivables of $33.8 million and inventories of $237.3 million. The company currently has total current assets of $718.5 million. Comparatively, the company has current liabilities of $238.0 million, of which the largest portion, $110.1 million, is attributable to income tax payable, followed by accrued expenses of $54.4 million.

In terms of outlook, CEO Joe Bayern stated, “With our revenue projected to increase to $305 million to $315 million in the second quarter, we also expect to generate significant improvements in terms of achieving positive net income and positive operating cash flows in the back half of 2021.”

Curaleaf Holdings last traded at $17.35 on the CSE.


Information for this briefing was found via Sedar and Curaleaf Holdings. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Aurora Accuses Curaleaf of Trying to Buy It ‘at the Lowest Price Possible’

Aurora Cannabis (TSX: ACB) has escalated its defense against Curaleaf Holdings (TSX: CURA), arguing that...

Wednesday, August 19, 2026, 10:01:50 AM

Curaleaf Seeks Reorganization Of US Assets To List On TSX

Curaleaf Holdings (CSE: CURA) is looking to be the second multi-state cannabis operator to list...

Monday, July 17, 2023, 07:43:04 PM

Curaleaf Opens Its 100th Retail Cannabis Location

Curaleaf Holdings (CSE: CURA) this morning achieved a milestone, with company opening its 100th national...

Wednesday, February 10, 2021, 09:07:35 AM

Curaleaf Breaks Trend, Begins Hiring Due To Pandemic Demands

It appears that Curaleaf Holdings (CSE: CURA) has broken the latest trend in the cannabis...

Tuesday, March 24, 2020, 08:52:04 AM

Curaleaf Closes European Transaction, Immediately Sells 31.5% Stake To Undisclosed Strategic Investor

Curaleaf Holdings (CSE: CURA) this morning announced the completion of EMMAC Life Sciences, a vertically...

Wednesday, April 7, 2021, 08:38:43 AM